Overall, these observations suggest that ILK regulates the JNK/c-JUN pathway in cisplatin-resistant ovarian cancer via modulation of DUSP8, MARVELD3, PDCD4, MAPK8IP1, MAPK8IP2, and HIPK3. Here, ILK is linked to ovarian cancer.